Induction of papillomas with a high probability of conversion to malignancy - PubMed (original) (raw)
Induction of papillomas with a high probability of conversion to malignancy
H Hennings et al. Carcinogenesis. 1985 Nov.
Abstract
Papillomas induced by standard initiation-promotion protocols progress to carcinomas at a low frequency. Experimental protocols were developed to elicit papillomas with a higher probability of malignant conversion. SENCAR mice initiated by 7,12-dimethylbenz[a]anthracene were promoted by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) for 5, 10, 20 or 40 weeks. With promotion for 10 weeks or more, a peak of papilloma incidence at 16-20 weeks was followed by a 35-40% decrease within 3 months. A much lower papilloma response was seen in mice promoted for 5 weeks, but these papillomas persisted. The yield of malignant tumors was similar in all four groups, with 20-25 carcinomas per group of 30 mice. Thus, the papillomas induced by the first few TPA treatments are much more likely to progress to carcinomas than those which appear later. In a separate study, initiated Charles River CD-1 mice were promoted with TPA for either 12 or 52 weeks. Acetone solvent treatment was begun at Week 13 in the group treated 12 weeks with TPA. At Week 16, the papilloma incidence was identical in the two groups of mice. However, by Week 28, the papilloma yield in the continuous TPA group had increased and was twice that of the acetone group, in which papillomas had regressed. The first carcinoma arose 14 weeks earlier with continuous TPA, but the final number of carcinomas per group of 40 mice was 17 with TPA and 20 with acetone. Neither the increase in papillomas in TPA-treated mice nor the regression of papillomas after cessation of promotion with TPA affected the final carcinoma yield. This result suggests that TPA-dependent papillomas are very unlikely to progress to carcinomas. In a third experiment, promotion of initiated SENCAR mice with mezerein resulted in a small number of papillomas which had a much higher probability of progression to carcinomas than the large number of papillomas promoted by TPA. The ability to induce papillomas promoted by TPA. The ability to induce papillomas with a known probability of conversion to carcinomas will facilitate the identification of markers associated with malignant progression.
Similar articles
- Protection against induction of mouse skin papillomas with low and high risk of conversion to malignancy by green tea polyphenols.
Katiyar SK, Mohan RR, Agarwal R, Mukhtar H. Katiyar SK, et al. Carcinogenesis. 1997 Mar;18(3):497-502. doi: 10.1093/carcin/18.3.497. Carcinogenesis. 1997. PMID: 9067548 - Vitamin E is a complete tumor promoter in mouse skin.
Mitchel RE, McCann R. Mitchel RE, et al. Carcinogenesis. 1993 Apr;14(4):659-62. doi: 10.1093/carcin/14.4.659. Carcinogenesis. 1993. PMID: 8472330 - Further characterization of skin tumor promotion and progression by mezerein in SENCAR mice.
Ewing MW, Conti CJ, Phillips JL, Slaga TJ, DiGiovanni J. Ewing MW, et al. J Natl Cancer Inst. 1989 May 3;81(9):676-82. doi: 10.1093/jnci/81.9.676. J Natl Cancer Inst. 1989. PMID: 2496233 - Effects of dose and duration of treatment with the tumor-promoting agent, 12-O-tetradecanoylphorbol-13-acetate on mouse skin carcinogenesis.
Verma AK, Boutwell RK. Verma AK, et al. Carcinogenesis. 1980 Mar;1(3):271-6. doi: 10.1093/carcin/1.3.271. Carcinogenesis. 1980. PMID: 22283009 - Sensitivity of subpopulations of mouse skin papillomas to malignant conversion by urethane or 4-nitroquinoline N-oxide.
Hennings H, Shores R, Balaschak M, Yuspa SH. Hennings H, et al. Cancer Res. 1990 Feb 1;50(3):653-7. Cancer Res. 1990. PMID: 2105160
Cited by
- Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression.
Brown K, Buchmann A, Balmain A. Brown K, et al. Proc Natl Acad Sci U S A. 1990 Jan;87(2):538-42. doi: 10.1073/pnas.87.2.538. Proc Natl Acad Sci U S A. 1990. PMID: 2105486 Free PMC article. - Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion.
Glick AB, Kulkarni AB, Tennenbaum T, Hennings H, Flanders KC, O'Reilly M, Sporn MB, Karlsson S, Yuspa SH. Glick AB, et al. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6076-80. doi: 10.1073/pnas.90.13.6076. Proc Natl Acad Sci U S A. 1993. PMID: 7687059 Free PMC article. - Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression.
Wong CE, Yu JS, Quigley DA, To MD, Jen KY, Huang PY, Del Rosario R, Balmain A. Wong CE, et al. Genes Dev. 2013 Mar 15;27(6):670-82. doi: 10.1101/gad.210427.112. Genes Dev. 2013. PMID: 23512660 Free PMC article. - Wealth of opportunity - the C1 domain as a target for drug development.
Blumberg PM, Kedei N, Lewin NE, Yang D, Czifra G, Pu Y, Peach ML, Marquez VE. Blumberg PM, et al. Curr Drug Targets. 2008 Aug;9(8):641-52. doi: 10.2174/138945008785132376. Curr Drug Targets. 2008. PMID: 18691011 Free PMC article. Review. - Transfection of the EJ rasHa gene into keratinocytes derived from carcinogen-induced mouse papillomas causes malignant progression.
Harper JR, Roop DR, Yuspa SH. Harper JR, et al. Mol Cell Biol. 1986 Sep;6(9):3144-9. doi: 10.1128/mcb.6.9.3144-3149.1986. Mol Cell Biol. 1986. PMID: 2431297 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources